JP2005529152A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529152A5
JP2005529152A5 JP2004505078A JP2004505078A JP2005529152A5 JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5 JP 2004505078 A JP2004505078 A JP 2004505078A JP 2004505078 A JP2004505078 A JP 2004505078A JP 2005529152 A5 JP2005529152 A5 JP 2005529152A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dose
antibody
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004505078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/015874 external-priority patent/WO2003097082A2/en
Publication of JP2005529152A publication Critical patent/JP2005529152A/ja
Publication of JP2005529152A5 publication Critical patent/JP2005529152A5/ja
Pending legal-status Critical Current

Links

JP2004505078A 2002-05-17 2003-05-16 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療 Pending JP2005529152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15074202A 2002-05-17 2002-05-17
US38331002P 2002-05-22 2002-05-22
PCT/US2003/015874 WO2003097082A2 (en) 2002-05-17 2003-05-16 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Publications (2)

Publication Number Publication Date
JP2005529152A JP2005529152A (ja) 2005-09-29
JP2005529152A5 true JP2005529152A5 (enExample) 2006-07-06

Family

ID=29552737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004505078A Pending JP2005529152A (ja) 2002-05-17 2003-05-16 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療

Country Status (5)

Country Link
EP (1) EP1506002A4 (enExample)
JP (1) JP2005529152A (enExample)
AU (1) AU2003231802A1 (enExample)
CA (1) CA2486147A1 (enExample)
WO (1) WO2003097082A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322289T2 (de) 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
EA013118B1 (ru) * 2005-01-27 2010-02-26 Новиммун С.А. Антитела против интерферона-гамма и способы их применения
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
KR20100126515A (ko) * 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
BR112014012607A2 (pt) 2011-11-23 2017-06-20 Amgen Inc métodos de tratamento usando um inibidor de interferon gama
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
BR112017023867A2 (pt) 2015-05-07 2018-07-24 Novimmune Sa métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
DE69322289T2 (de) * 1992-12-29 1999-05-20 Genentech, Inc., South San Francisco, Calif. Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
CA2352572C (en) * 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
US20050019323A1 (en) * 2002-05-22 2005-01-27 Protein Design Labs, Inc. Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies

Similar Documents

Publication Publication Date Title
JP2019196370A5 (enExample)
JP2015187125A5 (enExample)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2020002172A5 (enExample)
JP2017031213A5 (enExample)
JP2016074740A5 (enExample)
JP2014114288A5 (enExample)
KR101900520B1 (ko) 복합 조성물
JP2005520778A5 (enExample)
JP2013533858A5 (enExample)
JP2016516016A5 (enExample)
JP2017537105A5 (enExample)
RU2014101207A (ru) Новые показания к применению при лечении антителами против il-1-бета
JP2018531938A5 (enExample)
FI3356386T3 (fi) Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
JP2018532715A5 (enExample)
JP2015172060A5 (enExample)
JP2019521156A5 (enExample)
JP2020515530A5 (enExample)
JP2005506345A5 (enExample)
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
JP2006508039A5 (enExample)
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
JP2005529152A5 (enExample)
JP2006514681A5 (enExample)